首页 > 最新文献

Evidence report/technology assessment最新文献

英文 中文
Antiretroviral (ARV) drug resistance in the developing world. 发展中国家的抗逆转录病毒(ARV)耐药性。
Paul Shekelle, Margaret Maglione, Matthew Bidwell Geotz, Glenn Wagner, Zhen Wang, Lara Hilton, Jason Carter, Susan Chen, Carlo Tringle, Walter Mojica, Synde Newberry

Objectives: To describe the overall prevalence of ARV resistance in the developing world, focusing on: (1) treatment naïve populations, (2) the resistance consequences of prevention of mother to child transmission (pMTCT) drug regimens, and (3) the relationship of medication adherence to resistance.

Data sources: We searched PubMed(R), EMBASE, the Cochrane Controlled Clinical Trials Register Database, and the Cochrane Database of Reviews of Effectiveness (DARE). Additional sources of evidence included the Stanford University HIV Drug Resistance Database; reports of WATCH: Worldwide Analysis of Resistance Transmission over Time of Chronically and Acute Infected HIV-1 infected persons; a recent unpublished pMTCT overview; and various conference proceedings. Studies that did not report original research, that reported data already reported in another article, and case studies of fewer than 20 individuals were excluded. Of 1,122 titles identified, 117 journal articles and presentations were included.

Review methods: We abstracted data on geographic region, number of participants, subject demographics, HIV viral clade, medications taken (if any), years of data collection, how people were selected for resistance testing, and how and when resistance was assessed. Because of study heterogeneity, pooling was not possible; thus, the data are summarized qualitatively. Differences by region, population group, and HIV viral clade are described.

Results: The patterns of ARV resistance among treatment naïve populations worldwide appear to reflect geographic trends in use of ARV medications. A worldwide surveillance program (WATCH) found the rate of resistance (to any drug) among treatment naïve individuals was 5.5 percent in Africa, 7.4 percent in East Asia, 5.7 percent in Southeast Asia, and 6.4 percent in Latin America, lower than in North America (11.4 percent) and Europe (10.6 percent). Resistance data on HIV clades other than A, B, C, and D were too scarce to permit reliable conclusions. We also identified very few studies designed to assess the effect of health services delivery factors or medication adherence on the development of resistance in patients in developing countries. Evidence provided by longitudinal analyses suggests that, among women taking intrapartum single dose nevirapine (SD-NVP) to prevent mother-to-child transmission of HIV, both the overall prevalence of NNRTI resistance as well as the frequency of mutant virus in the overall viral population decreases with time since SD-NVP prophylaxis was received.

Conclusions: In future resistance studies, rare HIV clades should be over-sampled in order to provide statistically meaningful data. Resistance surveillance programs should be maintained throughout the developing world, and data should be reported and analyzed in a consistent and timely manner. Where resources permit, studies of

目的:描述发展中国家抗逆转录病毒耐药性的总体流行情况,重点关注:(1)治疗naïve人群,(2)预防母婴传播(pMTCT)药物方案的耐药性后果,以及(3)药物依从性与耐药性的关系。数据来源:检索PubMed(R)、EMBASE、Cochrane对照临床试验注册数据库和Cochrane疗效评价数据库(DARE)。其他证据来源包括斯坦福大学艾滋病毒耐药性数据库;观察报告:慢性和急性感染HIV-1感染者耐药性随时间传播的全球分析;最近未发表的预防母婴传播概述;以及各种会议记录。未报告原始研究的研究、报告已在另一篇文章中报告的数据的研究,以及少于20人的案例研究被排除在外。在确定的1122个标题中,包括117篇期刊文章和演讲。回顾方法:我们提取了地理区域、参与者数量、受试者人口统计学、HIV病毒进化支、服用药物(如果有的话)、数据收集年份、如何选择人群进行耐药性测试以及如何和何时评估耐药性的数据。由于研究的异质性,不可能合并;因此,对数据进行了定性总结。不同地区、人口群体和HIV病毒进化分支的差异被描述。结果:世界范围内治疗人群中ARV耐药模式似乎反映了ARV药物使用的地理趋势。一项全球监测计划(WATCH)发现,在接受治疗的naïve个体中(对任何药物)的耐药率在非洲为5.5%,东亚为7.4%,东南亚为5.7%,拉丁美洲为6.4%,低于北美(11.4%)和欧洲(10.6%)。除A、B、C和D以外的HIV分支的耐药数据太少,无法得出可靠的结论。我们还发现,很少有研究旨在评估卫生服务提供因素或药物依从性对发展中国家患者耐药性发展的影响。纵向分析提供的证据表明,在分娩时服用单剂量奈韦拉平(SD-NVP)预防HIV母婴传播的妇女中,NNRTI耐药的总体流行率以及总病毒群体中突变病毒的频率都随着接受SD-NVP预防的时间而降低。结论:在未来的耐药研究中,应该对罕见的HIV分支进行过度采样,以提供有统计学意义的数据。应在整个发展中国家维持耐药性监测计划,并以一致和及时的方式报告和分析数据。在资源允许的情况下,发展中地区的依从性研究应进行耐药性测试。
{"title":"Antiretroviral (ARV) drug resistance in the developing world.","authors":"Paul Shekelle,&nbsp;Margaret Maglione,&nbsp;Matthew Bidwell Geotz,&nbsp;Glenn Wagner,&nbsp;Zhen Wang,&nbsp;Lara Hilton,&nbsp;Jason Carter,&nbsp;Susan Chen,&nbsp;Carlo Tringle,&nbsp;Walter Mojica,&nbsp;Synde Newberry","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the overall prevalence of ARV resistance in the developing world, focusing on: (1) treatment naïve populations, (2) the resistance consequences of prevention of mother to child transmission (pMTCT) drug regimens, and (3) the relationship of medication adherence to resistance.</p><p><strong>Data sources: </strong>We searched PubMed(R), EMBASE, the Cochrane Controlled Clinical Trials Register Database, and the Cochrane Database of Reviews of Effectiveness (DARE). Additional sources of evidence included the Stanford University HIV Drug Resistance Database; reports of WATCH: Worldwide Analysis of Resistance Transmission over Time of Chronically and Acute Infected HIV-1 infected persons; a recent unpublished pMTCT overview; and various conference proceedings. Studies that did not report original research, that reported data already reported in another article, and case studies of fewer than 20 individuals were excluded. Of 1,122 titles identified, 117 journal articles and presentations were included.</p><p><strong>Review methods: </strong>We abstracted data on geographic region, number of participants, subject demographics, HIV viral clade, medications taken (if any), years of data collection, how people were selected for resistance testing, and how and when resistance was assessed. Because of study heterogeneity, pooling was not possible; thus, the data are summarized qualitatively. Differences by region, population group, and HIV viral clade are described.</p><p><strong>Results: </strong>The patterns of ARV resistance among treatment naïve populations worldwide appear to reflect geographic trends in use of ARV medications. A worldwide surveillance program (WATCH) found the rate of resistance (to any drug) among treatment naïve individuals was 5.5 percent in Africa, 7.4 percent in East Asia, 5.7 percent in Southeast Asia, and 6.4 percent in Latin America, lower than in North America (11.4 percent) and Europe (10.6 percent). Resistance data on HIV clades other than A, B, C, and D were too scarce to permit reliable conclusions. We also identified very few studies designed to assess the effect of health services delivery factors or medication adherence on the development of resistance in patients in developing countries. Evidence provided by longitudinal analyses suggests that, among women taking intrapartum single dose nevirapine (SD-NVP) to prevent mother-to-child transmission of HIV, both the overall prevalence of NNRTI resistance as well as the frequency of mutant virus in the overall viral population decreases with time since SD-NVP prophylaxis was received.</p><p><strong>Conclusions: </strong>In future resistance studies, rare HIV clades should be over-sampled in order to provide statistically meaningful data. Resistance surveillance programs should be maintained throughout the developing world, and data should be reported and analyzed in a consistent and timely manner. Where resources permit, studies of","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 156","pages":"1-74"},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27125663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of primary and secondary osteoarthritis of the knee. 膝关节原发性和继发性骨关节炎的治疗。
David J Samson, Mark D Grant, Thomas A Ratko, Claudia J Bonnell, Kathleen M Ziegler, Naomi Aronson

Objectives: Systematic review of outcomes of three treatments for osteoarthritis (OA) of the knee: intra-articular viscosupplementation; oral glucosamine, chondroitin or the combination; and arthroscopic lavage or debridement.

Data sources: We abstracted data from: 42 randomized, controlled trials (RCTs) of viscosupplementation, all but one synthesized among six meta-analyses; 21 RCTs of glucosamine/chondroitin, 16 synthesized among 6 meta-analyses; and 23 articles on arthroscopy. The search included foreign-language studies and relevant conference proceedings.

Review methods: The review methods were defined prospectively in a written protocol. We sought systematic reviews, meta-analyses, and RCTs published in full or in abstract. Where randomized trials were few, we sought other study designs. We independently assessed the quality of all primary studies.

Results: Viscosupplementation trials generally report positive effects on pain and function scores compared to placebo, but the evidence on clinical benefit is uncertain, due to variable trial quality, potential publication bias, and unclear clinical significance of the changes reported. The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), a large (n=1,583), high-quality, National Institutes of Health-funded, multicenter RCT showed no significant difference compared to placebo. Glucosamine sulfate has been reported to be more effective than glucosamine hydrochloride, which was used in GAIT, but the evidence is not sufficient to draw conclusions. Clinical studies of glucosamine effect on glucose metabolism are short term, or if longer (e.g., 3 years), excluded patients with metabolic disorders. The best available evidence for arthroscopy, a single sham-controlled RCT (n=180), showed that arthroscopic lavage with or without debridement was equivalent to placebo. The main limitations of this trial are the use of a single surgeon and enrollment of patients at a single Veterans Affairs Medical Center. No studies reported separately on patients with secondary OA of the knee. The only comparative study was an underpowered, poor-quality trial comparing viscosupplementation to arthroscopy with debridement.

Conclusions: Osteoarthritis of the knee is a common condition. The three interventions reviewed in this report are widely used in the treatment of OA of the knee, yet the best available evidence does not clearly demonstrate clinical benefit. Uncertainty regarding clinical benefit can be resolved only by rigorous, multicenter RCTs. In addition, given the public health impact of OA of the knee, research on new approaches to prevention and treatment should be given high priority.

目的:系统回顾三种治疗膝关节骨关节炎(OA)的结果:关节内粘剂补充;口服氨基葡萄糖、软骨素或联合用药;关节镜冲洗或清创。数据来源:我们提取的数据来自:42项关于粘剂补充的随机对照试验(rct),除一项外,其余试验均来自6项荟萃分析;21项葡萄糖胺/软骨素随机对照试验,其中16项在6项meta分析中合成;还有23篇关于关节镜的文章。搜索包括外语研究和相关的会议记录。评价方法:前瞻性地在书面方案中定义评价方法。我们检索了全文或摘要发表的系统综述、荟萃分析和随机对照试验。在随机试验较少的情况下,我们寻求其他研究设计。我们独立评估了所有初步研究的质量。结果:与安慰剂相比,粘胶补充剂试验通常报告了对疼痛和功能评分的积极影响,但由于试验质量的变化、潜在的发表偏倚以及所报道的变化的临床意义不明确,临床益处的证据尚不确定。葡萄糖胺/软骨素关节炎干预试验(步态)是一项大型(n= 1583)、高质量、美国国立卫生研究院资助的多中心随机对照试验,与安慰剂相比无显著差异。据报道,硫酸氨基葡萄糖比用于步态的盐酸氨基葡萄糖更有效,但证据不足以得出结论。葡萄糖胺对葡萄糖代谢影响的临床研究是短期的,如果更长(如3年),则排除了代谢紊乱患者。关节镜检查的最佳证据是一项假对照随机对照试验(n=180),该试验显示,关节镜下洗胃伴或不伴清创与安慰剂效果相当。该试验的主要限制是使用单一外科医生和在单一退伍军人事务医疗中心登记患者。没有关于继发性膝关节炎患者的单独研究报道。唯一的比较研究是一项力度不足、质量较差的试验,该试验比较了关节镜下补充粘胶和清创。结论:膝关节骨关节炎是一种常见的疾病。本报告中回顾的三种干预措施被广泛用于治疗膝关节OA,但现有的最佳证据并不能清楚地证明其临床益处。临床获益的不确定性只能通过严格的多中心随机对照试验来解决。此外,考虑到膝关节OA对公众健康的影响,研究新的预防和治疗方法应得到高度重视。
{"title":"Treatment of primary and secondary osteoarthritis of the knee.","authors":"David J Samson,&nbsp;Mark D Grant,&nbsp;Thomas A Ratko,&nbsp;Claudia J Bonnell,&nbsp;Kathleen M Ziegler,&nbsp;Naomi Aronson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Systematic review of outcomes of three treatments for osteoarthritis (OA) of the knee: intra-articular viscosupplementation; oral glucosamine, chondroitin or the combination; and arthroscopic lavage or debridement.</p><p><strong>Data sources: </strong>We abstracted data from: 42 randomized, controlled trials (RCTs) of viscosupplementation, all but one synthesized among six meta-analyses; 21 RCTs of glucosamine/chondroitin, 16 synthesized among 6 meta-analyses; and 23 articles on arthroscopy. The search included foreign-language studies and relevant conference proceedings.</p><p><strong>Review methods: </strong>The review methods were defined prospectively in a written protocol. We sought systematic reviews, meta-analyses, and RCTs published in full or in abstract. Where randomized trials were few, we sought other study designs. We independently assessed the quality of all primary studies.</p><p><strong>Results: </strong>Viscosupplementation trials generally report positive effects on pain and function scores compared to placebo, but the evidence on clinical benefit is uncertain, due to variable trial quality, potential publication bias, and unclear clinical significance of the changes reported. The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), a large (n=1,583), high-quality, National Institutes of Health-funded, multicenter RCT showed no significant difference compared to placebo. Glucosamine sulfate has been reported to be more effective than glucosamine hydrochloride, which was used in GAIT, but the evidence is not sufficient to draw conclusions. Clinical studies of glucosamine effect on glucose metabolism are short term, or if longer (e.g., 3 years), excluded patients with metabolic disorders. The best available evidence for arthroscopy, a single sham-controlled RCT (n=180), showed that arthroscopic lavage with or without debridement was equivalent to placebo. The main limitations of this trial are the use of a single surgeon and enrollment of patients at a single Veterans Affairs Medical Center. No studies reported separately on patients with secondary OA of the knee. The only comparative study was an underpowered, poor-quality trial comparing viscosupplementation to arthroscopy with debridement.</p><p><strong>Conclusions: </strong>Osteoarthritis of the knee is a common condition. The three interventions reviewed in this report are widely used in the treatment of OA of the knee, yet the best available evidence does not clearly demonstrate clinical benefit. Uncertainty regarding clinical benefit can be resolved only by rigorous, multicenter RCTs. In addition, given the public health impact of OA of the knee, research on new approaches to prevention and treatment should be given high priority.</p>","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 157","pages":"1-157"},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27124547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and safety of vitamin D in relation to bone health. 维生素D对骨骼健康的有效性和安全性。
Ann Cranney, Tanya Horsley, Siobhan O'Donnell, Hope Weiler, Lorri Puil, Daylily Ooi, Stephanie Atkinson, Leanne Ward, David Moher, David Hanley, Manchung Fang, Fatemeh Yazdi, Chantelle Garritty, Margaret Sampson, Nick Barrowman, Alex Tsertsvadze, Vasil Mamaladze

Objectives: To review and synthesize the literature in the following areas: the association of specific circulating 25(OH)D concentrations with bone health outcomes in children, women of reproductive age, postmenopausal women and elderly men; the effect of dietary intakes (foods fortified with vitamin D and/or vitamin D supplementation) and sun exposure on serum 25(OH)D; the effect of vitamin D on bone mineral density (BMD) and fracture or fall risk; and the identification of potential harms of vitamin D above current reference intakes.

Data sources: MEDLINE(R) (1966-June Week 3 2006); Embase (2002-2006 Week 25); CINAHL (1982-June Week 4, 2006); AMED (1985 to June 2006); Biological Abstracts (1990-February 2005); and the Cochrane Central Register of Controlled Trials (2nd Quarter 2006).

Review methods: Two independent reviewers completed a multi-level process of screening the literature to identify eligible studies (title and abstract, followed by full text review, and categorization of study design per key question). To minimize bias, study design was limited to randomized controlled trials (RCTs) wherever possible. Study criteria for question one were broadened to include observational studies due to a paucity of available RCTs, and question four was restricted to systematic reviews to limit scope. Data were abstracted in duplicate and study quality assessed. Differences in opinion were resolved through consensus or adjudication. If clinically relevant and statistically feasible, meta-analyses of RCTs on vitamin D supplementation and bone health outcomes were conducted, with exploration of heterogeneity. When meta-analysis was not feasible, a qualitative systematic review of eligible studies was conducted.

Results: 167 studies met our eligibility criteria (112 RCTs, 19 prospective cohorts, 30 case-controls and six before-after studies). The largest body of evidence on vitamin D status and bone health was in older adults with a lack of studies in premenopausal women and infants, children and adolescents. The quality of RCTs was highest in the vitamin D efficacy trials for prevention of falls and/or fractures in older adults. There was fair evidence of an association between low circulating 25(OH)D concentrations and established rickets. However, the specific 25(OH)D concentrations associated with rickets is uncertain, given the lack of studies in populations with dietary calcium intakes similar to North American diets and the different methods used to determine 25(OH)D concentrations. There was inconsistent evidence of an association of circulating 25(OH)D with bone mineral content in infants, and fair evidence that serum 25(OH)D is inversely associated with serum PTH. In adolescents, there was fair evidence for an association between 25(OH)D levels and changes in BMD. There were very few studies in pregnant and lactating women, and insufficient evidence for

目的:综述和综合以下领域的文献:儿童、育龄妇女、绝经后妇女和老年男性的特定循环25(OH)D浓度与骨骼健康结果的关系;膳食摄入量(含维生素D强化和/或补充维生素D的食物)和日晒对血清25(OH)D的影响;维生素D对骨密度(BMD)和骨折或跌倒风险的影响;以及确定维生素D高于当前参考摄入量的潜在危害。数据来源:MEDLINE(R)(1966- 2006年6月第3周);Embase(2002-2006第25周);(1982- 2006年6月第4周);(1985年至2006年6月);生物文摘(1990- 2005年2月);和Cochrane中央对照试验登记(2006年第二季度)。两名独立的审稿人完成了多层次的文献筛选过程,以确定符合条件的研究(标题和摘要,然后是全文审查,以及每个关键问题的研究设计分类)。为了尽量减少偏倚,研究设计尽可能限于随机对照试验(rct)。由于缺乏可用的随机对照试验,问题1的研究标准被扩大到包括观察性研究,问题4被限制到系统评价以限制范围。资料一式两份提取,并评估研究质量。意见分歧通过协商一致或裁决来解决。如果临床相关且统计可行,则对维生素D补充和骨骼健康结果的随机对照试验进行荟萃分析,并探索异质性。当荟萃分析不可行时,对符合条件的研究进行定性系统评价。结果:167项研究符合我们的入选标准(112项随机对照试验,19项前瞻性队列,30例病例对照和6项前后对照研究)。关于维生素D状况和骨骼健康的最大证据是老年人,缺乏对绝经前妇女、婴儿、儿童和青少年的研究。在维生素D预防老年人跌倒和/或骨折的功效试验中,随机对照试验的质量最高。有充分的证据表明低循环25(OH)D浓度与佝偻病之间存在关联。然而,考虑到缺乏对饮食钙摄入量与北美饮食相似的人群的研究以及测定25(OH)D浓度的不同方法,佝偻病的具体25(OH)D浓度是不确定的。有不一致的证据表明循环25(OH)D与婴儿骨矿物质含量的关联,而公平的证据表明血清25(OH)D与血清甲状旁腺激素呈负相关。在青少年中,有充分的证据表明25(OH)D水平与骨密度变化之间存在关联。对孕妇和哺乳期妇女的研究非常少,并且没有足够的证据表明血清25(OH)D与哺乳期骨密度变化之间存在关联,并且有充分的证据表明血清25(OH)D与甲状旁腺激素呈负相关。在老年人中,有充分的证据表明血清25(OH)D与跌倒呈负相关,有充分的证据表明血清25(OH)D与BMD呈正相关,而与骨折相关的证据不一致。25(OH)D测定的不精确性可能导致25(OH)D阈值的变化,低于25(OH)D阈值,骨折、跌倒或骨质流失的风险增加。有充分的证据表明,维生素D强化食品的摄入量(11项随机对照试验)持续增加了年轻人和老年人的血清25(OH)D。8个关于紫外线(UV)-B辐射(人工照射和太阳照射)的随机试验在确定确切的紫外线(UV)-B剂量和25(OH)D测定方面规模小且不均匀,但对血清25(OH)D浓度有积极影响。不可能确定25(OH)D水平如何因种族、防晒霜使用或纬度而变化。74项试验检验了维生素D(3)或D(2)对25(OH)D浓度的影响。大多数试验使用的是维生素D(3),而且大多数试验招募的是老年人。在三个试验中,与维生素D(2)相比,血清25(OH)D浓度对维生素D(3)的反应更大,这可能是由于维生素D(2)的清除速度更快,以及其他机制。16项维生素D试验的荟萃分析(3)与每日剂量/= 400 IU时血清25(OH)D的剂量反应效应一致。异质性的探索性分析表明,每增加100单位维生素D,血清25(OH)D增加1 - 2 nmol/L,具有显著的正相关,尽管在调整剂量后异质性仍然存在。与安慰剂相比,在老年人中,维生素D(3)与钙的结合导致骨密度小幅增加,尽管由于治疗持续时间和骨密度部位的变化,定量合成受到限制。补充维生素D减少骨折的证据在15个试验中是不一致的。 使用维生素D(3)(每天700 - 800国际单位)和钙(500 - 1200毫克)的试验的综合结果与骨折的益处一致,尽管在亚组分析中,获益主要是在老年机构妇女中(来自两个试验的公平证据)。在14项随机对照试验中,关于降低跌倒风险的证据并不一致。然而,亚组分析显示维生素D对绝经后妇女有益,在试验中使用维生素D(3)加钙。此外,当六个充分确定跌倒的试验结合在一起时,维生素D可以降低跌倒的风险。跌倒和骨折试验的局限性包括维生素D补充依从性差,维生素D状态评估不完整以及随访损失大。我们没有发现任何系统的综述来讨论阳光照射水平是否足以维持血清25(OH)D浓度,但能将黑色素瘤和非黑色素瘤皮肤癌的风险降至最低。从现有的试验中几乎没有证据表明维生素D超过当前的参考摄入量是有害的。在大多数试验中,高钙血症和高钙尿症的报告与临床相关事件无关。妇女健康倡议的研究确实报告了50至79岁的绝经后妇女,其每日维生素D(3)摄入量为400国际单位(50至70年的参考摄入量,70年以上的参考摄入量低于参考摄入量)和1000毫克钙的肾结石发生率有小幅增加。肾结石的增加相当于每10,000人年暴露5.7例。在这个试验中,妇女的钙摄入量比大多数绝经后妇女高。结论:这些结果强调了对婴儿、儿童、绝经前妇女和不同种族或民族群体进行更多高质量研究的必要性。有充分的证据表明,循环25(OH)D浓度与一些骨骼健康结果(既定佝偻病、甲状旁腺病、跌倒、骨密度)之间存在关联。然而,其他结果(如婴儿BMC和成人骨折)的相关性证据并不一致。由于不同的25(OH)D测定方法不精确,很难确定最佳骨骼健康的循环25(OH)D的特定阈值。需要标准参比制剂,以便准确可靠地测量和验证血清25(OH)D。在大多数试验中,维生素D和钙的作用是不能分开的。与安慰剂相比,补充维生素D(3) (>700 IU/天)和钙对骨密度有小的有益影响,并降低骨折和跌倒的风险,尽管益处可能仅限于特定的亚组。维生素D摄入量高于目前的饮食参考摄入量与不良事件风险增加无关。然而,大多数高剂量维生素D的试验并没有充分设计来评估长期危害。
{"title":"Effectiveness and safety of vitamin D in relation to bone health.","authors":"Ann Cranney,&nbsp;Tanya Horsley,&nbsp;Siobhan O'Donnell,&nbsp;Hope Weiler,&nbsp;Lorri Puil,&nbsp;Daylily Ooi,&nbsp;Stephanie Atkinson,&nbsp;Leanne Ward,&nbsp;David Moher,&nbsp;David Hanley,&nbsp;Manchung Fang,&nbsp;Fatemeh Yazdi,&nbsp;Chantelle Garritty,&nbsp;Margaret Sampson,&nbsp;Nick Barrowman,&nbsp;Alex Tsertsvadze,&nbsp;Vasil Mamaladze","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>To review and synthesize the literature in the following areas: the association of specific circulating 25(OH)D concentrations with bone health outcomes in children, women of reproductive age, postmenopausal women and elderly men; the effect of dietary intakes (foods fortified with vitamin D and/or vitamin D supplementation) and sun exposure on serum 25(OH)D; the effect of vitamin D on bone mineral density (BMD) and fracture or fall risk; and the identification of potential harms of vitamin D above current reference intakes.</p><p><strong>Data sources: </strong>MEDLINE(R) (1966-June Week 3 2006); Embase (2002-2006 Week 25); CINAHL (1982-June Week 4, 2006); AMED (1985 to June 2006); Biological Abstracts (1990-February 2005); and the Cochrane Central Register of Controlled Trials (2nd Quarter 2006).</p><p><strong>Review methods: </strong>Two independent reviewers completed a multi-level process of screening the literature to identify eligible studies (title and abstract, followed by full text review, and categorization of study design per key question). To minimize bias, study design was limited to randomized controlled trials (RCTs) wherever possible. Study criteria for question one were broadened to include observational studies due to a paucity of available RCTs, and question four was restricted to systematic reviews to limit scope. Data were abstracted in duplicate and study quality assessed. Differences in opinion were resolved through consensus or adjudication. If clinically relevant and statistically feasible, meta-analyses of RCTs on vitamin D supplementation and bone health outcomes were conducted, with exploration of heterogeneity. When meta-analysis was not feasible, a qualitative systematic review of eligible studies was conducted.</p><p><strong>Results: </strong>167 studies met our eligibility criteria (112 RCTs, 19 prospective cohorts, 30 case-controls and six before-after studies). The largest body of evidence on vitamin D status and bone health was in older adults with a lack of studies in premenopausal women and infants, children and adolescents. The quality of RCTs was highest in the vitamin D efficacy trials for prevention of falls and/or fractures in older adults. There was fair evidence of an association between low circulating 25(OH)D concentrations and established rickets. However, the specific 25(OH)D concentrations associated with rickets is uncertain, given the lack of studies in populations with dietary calcium intakes similar to North American diets and the different methods used to determine 25(OH)D concentrations. There was inconsistent evidence of an association of circulating 25(OH)D with bone mineral content in infants, and fair evidence that serum 25(OH)D is inversely associated with serum PTH. In adolescents, there was fair evidence for an association between 25(OH)D levels and changes in BMD. There were very few studies in pregnant and lactating women, and insufficient evidence for","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 158","pages":"1-235"},"PeriodicalIF":0.0,"publicationDate":"2007-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27124546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of uterine fibroids: an update of the evidence. 子宫肌瘤的治疗:最新证据。
Meera Viswanathan, Katherine Hartmann, Nikki McKoy, Gretchen Stuart, Nicole Rankins, Patricia Thieda, Linda J Lux, Kathleen N Lohr

Objectives: The RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center (RTI-UNC EPC) systematically updated evidence on the management of uterine fibroids, specifically incidence and prevalence of fibroids, treatment outcomes, comparisons of treatment, modifiers of outcomes, and costs.

Data sources: We searched MEDLINE(R), Cochrane Collaboration resources, and Embase.

Review methods: We included studies published in English from February 2000 through August 2006. We excluded studies with low sample size (based on study design, cases series < 100 and cohorts < 40) or lack of relevance to uterine fibroids. Of 107 included studies, 3 were good quality, 56 fair, and 48 poor.

Results: The cumulative incidence by age 50 is 70 percent to 80 percent; black women are more likely to get fibroids at younger ages. Appearance of new fibroids and growth of existing fibroids after treatment are poorly studied. Trials of preoperative medical management indicate that treatment reduces fibroid volume but do not provide sufficient evidence of improvement in important operative outcomes. When women are treated for reasons other than symptom relief, such as when pregnancy is desired, weak evidence supports treating submucous fibroids via hysteroscopy. No well-conducted trials in U.S. populations directly compared treatment options, including the option of expectant management, or followed women to determine whether the intervention met their treatment objectives. Common procedures such as hysterectomy and myomectomy, including choice among types of myomectomy, still cannot be meaningfully compared. Studies comparing uterine artery embolization (UAE) with other procedures reported procedure time and length of stay favoring UAE, but inconsistency of the direction of effect for complications and absence of key information on longer-term outcomes suggest that this evidence base is inadequate to comment on the relative risks and benefits of UAE versus hysterectomy or myomectomy. Costs of fibroid treatment, despite shorter average lengths of stay, are rising.

Conclusions: The dearth of high-quality evidence supporting the effectiveness of most interventions for uterine fibroids is remarkable, given how common this problem is. The current state of the literature does not permit definitive conclusions about benefit, harm, or relative costs to help guide women's choices. Significant research gaps include well-conducted trials in U.S. populations that directly compare interventions on short- and, especially, long-term outcomes, studies on therapeutics for medical management, and information on treatment decisions for women who desire a pregnancy.

目的:北卡罗莱纳大学教堂山分校RTI国际循证实践中心(RTI- unc EPC)系统地更新了子宫肌瘤治疗的证据,特别是肌瘤的发病率和患病率、治疗结果、治疗比较、结果的修饰因素和成本。数据来源:检索MEDLINE(R)、Cochrane Collaboration资源和Embase。回顾方法:我们纳入了2000年2月至2006年8月间发表的英文研究。我们排除了低样本量的研究(基于研究设计,病例系列< 100例,队列< 40例)或与子宫肌瘤缺乏相关性的研究。在纳入的107项研究中,3项质量良好,56项一般,48项较差。结果:50岁累积发病率为70% ~ 80%;黑人女性在年轻时更容易得肌瘤。新肌瘤的出现和治疗后已有肌瘤的生长研究甚少。术前医疗管理的试验表明,治疗减少肌瘤体积,但没有提供足够的证据改善重要的手术结果。当妇女因症状缓解以外的原因而接受治疗时,例如当希望怀孕时,微弱的证据支持通过宫腔镜治疗粘膜下肌瘤。没有在美国人群中进行的良好试验直接比较治疗方案,包括预期治疗方案,或跟踪妇女以确定干预措施是否达到其治疗目标。常见的手术如子宫切除术和子宫肌瘤切除术,包括子宫肌瘤切除术类型的选择,仍然不能进行有意义的比较。比较子宫动脉栓塞(UAE)与其他手术的研究报告了UAE的手术时间和停留时间,但对并发症的影响方向不一致,缺乏长期结果的关键信息,这表明该证据基础不足以评论UAE与子宫切除术或子宫肌瘤切除术的相对风险和益处。尽管平均住院时间缩短,但肌瘤治疗的费用正在上升。结论:考虑到子宫肌瘤是多么常见的问题,缺乏高质量的证据支持大多数干预措施的有效性是值得注意的。目前的文献状况不允许关于收益、危害或相对成本的明确结论来帮助指导妇女的选择。重要的研究缺口包括在美国人群中进行的良好试验,这些试验直接比较了短期和特别是长期结果的干预措施,对医疗管理治疗方法的研究,以及对希望怀孕的妇女的治疗决定的信息。
{"title":"Management of uterine fibroids: an update of the evidence.","authors":"Meera Viswanathan,&nbsp;Katherine Hartmann,&nbsp;Nikki McKoy,&nbsp;Gretchen Stuart,&nbsp;Nicole Rankins,&nbsp;Patricia Thieda,&nbsp;Linda J Lux,&nbsp;Kathleen N Lohr","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>The RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center (RTI-UNC EPC) systematically updated evidence on the management of uterine fibroids, specifically incidence and prevalence of fibroids, treatment outcomes, comparisons of treatment, modifiers of outcomes, and costs.</p><p><strong>Data sources: </strong>We searched MEDLINE(R), Cochrane Collaboration resources, and Embase.</p><p><strong>Review methods: </strong>We included studies published in English from February 2000 through August 2006. We excluded studies with low sample size (based on study design, cases series < 100 and cohorts < 40) or lack of relevance to uterine fibroids. Of 107 included studies, 3 were good quality, 56 fair, and 48 poor.</p><p><strong>Results: </strong>The cumulative incidence by age 50 is 70 percent to 80 percent; black women are more likely to get fibroids at younger ages. Appearance of new fibroids and growth of existing fibroids after treatment are poorly studied. Trials of preoperative medical management indicate that treatment reduces fibroid volume but do not provide sufficient evidence of improvement in important operative outcomes. When women are treated for reasons other than symptom relief, such as when pregnancy is desired, weak evidence supports treating submucous fibroids via hysteroscopy. No well-conducted trials in U.S. populations directly compared treatment options, including the option of expectant management, or followed women to determine whether the intervention met their treatment objectives. Common procedures such as hysterectomy and myomectomy, including choice among types of myomectomy, still cannot be meaningfully compared. Studies comparing uterine artery embolization (UAE) with other procedures reported procedure time and length of stay favoring UAE, but inconsistency of the direction of effect for complications and absence of key information on longer-term outcomes suggest that this evidence base is inadequate to comment on the relative risks and benefits of UAE versus hysterectomy or myomectomy. Costs of fibroid treatment, despite shorter average lengths of stay, are rising.</p><p><strong>Conclusions: </strong>The dearth of high-quality evidence supporting the effectiveness of most interventions for uterine fibroids is remarkable, given how common this problem is. The current state of the literature does not permit definitive conclusions about benefit, harm, or relative costs to help guide women's choices. Significant research gaps include well-conducted trials in U.S. populations that directly compare interventions on short- and, especially, long-term outcomes, studies on therapeutics for medical management, and information on treatment decisions for women who desire a pregnancy.</p>","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 154","pages":"1-122"},"PeriodicalIF":0.0,"publicationDate":"2007-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27277322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meditation practices for health: state of the research. 冥想练习对健康的影响:研究现状。
Maria B Ospina, Kenneth Bond, Mohammad Karkhaneh, Lisa Tjosvold, Ben Vandermeer, Yuanyuan Liang, Liza Bialy, Nicola Hooton, Nina Buscemi, Donna M Dryden, Terry P Klassen

Objectives: To review and synthesize the state of research on a variety of meditation practices, including: the specific meditation practices examined; the research designs employed and the conditions and outcomes examined; the efficacy and effectiveness of different meditation practices for the three most studied conditions; the role of effect modifiers on outcomes; and the effects of meditation on physiological and neuropsychological outcomes.

Data sources: Comprehensive searches were conducted in 17 electronic databases of medical and psychological literature up to September 2005. Other sources of potentially relevant studies included hand searches, reference tracking, contact with experts, and gray literature searches.

Review methods: A Delphi method was used to develop a set of parameters to describe meditation practices. Included studies were comparative, on any meditation practice, had more than 10 adult participants, provided quantitative data on health-related outcomes, and published in English. Two independent reviewers assessed study relevance, extracted the data and assessed the methodological quality of the studies.

Results: Five broad categories of meditation practices were identified (Mantra meditation, Mindfulness meditation, Yoga, Tai Chi, and Qi Gong). Characterization of the universal or supplemental components of meditation practices was precluded by the theoretical and terminological heterogeneity among practices. Evidence on the state of research in meditation practices was provided in 813 predominantly poor-quality studies. The three most studied conditions were hypertension, other cardiovascular diseases, and substance abuse. Sixty-five intervention studies examined the therapeutic effect of meditation practices for these conditions. Meta-analyses based on low-quality studies and small numbers of hypertensive participants showed that TM(R), Qi Gong and Zen Buddhist meditation significantly reduced blood pressure. Yoga helped reduce stress. Yoga was no better than Mindfulness-based Stress Reduction at reducing anxiety in patients with cardiovascular diseases. No results from substance abuse studies could be combined. The role of effect modifiers in meditation practices has been neglected in the scientific literature. The physiological and neuropsychological effects of meditation practices have been evaluated in 312 poor-quality studies. Meta-analyses of results from 55 studies indicated that some meditation practices produced significant changes in healthy participants.

Conclusions: Many uncertainties surround the practice of meditation. Scientific research on meditation practices does not appear to have a common theoretical perspective and is characterized by poor methodological quality. Firm conclusions on the effects of meditation practices in healthcare cannot be drawn based on the available evidence. Future r

目的:回顾和综合各种冥想练习的研究现状,包括:研究的具体冥想练习;采用的研究设计、考察的条件和结果;在三种研究最多的情况下,不同的冥想练习的功效和效果;效果修饰词对结果的作用;以及冥想对生理和神经心理结果的影响。数据来源:对截至2005年9月的17个医学和心理学文献电子数据库进行了全面检索。其他可能相关研究的来源包括手工搜索、参考文献追踪、与专家接触和灰色文献搜索。回顾方法:采用德尔菲法开发一套参数来描述冥想练习。纳入的研究是比较的,涉及任何冥想练习,有10名以上的成人参与者,提供与健康有关的结果的定量数据,并以英语发表。两名独立审稿人评估了研究的相关性,提取了数据并评估了研究的方法学质量。结果:确定了五大类冥想练习(咒语冥想,正念冥想,瑜伽,太极和气功)。冥想实践的普遍或补充成分的特征被实践之间的理论和术语异质性所排除。813项主要质量较差的研究提供了关于冥想练习研究现状的证据。研究最多的三种疾病是高血压、其他心血管疾病和药物滥用。65项干预研究检查了冥想练习对这些疾病的治疗效果。基于低质量研究和少数高血压参与者的荟萃分析显示,TM(R)、气功和禅宗冥想可显著降低血压。瑜伽有助于减轻压力。在减少心血管疾病患者的焦虑方面,瑜伽并不比基于正念的减压法更好。没有药物滥用研究的结果可以合并。在科学文献中,冥想练习中的效果调节剂的作用一直被忽视。冥想练习的生理和神经心理影响已经在312项低质量研究中进行了评估。对55项研究结果的荟萃分析表明,一些冥想练习对健康参与者产生了显著的变化。结论:围绕冥想练习有许多不确定因素。关于冥想练习的科学研究似乎没有一个共同的理论视角,其特点是方法论质量差。根据现有的证据,无法得出关于冥想练习对医疗保健的影响的确切结论。未来关于冥想练习的研究必须在研究的设计和执行以及结果的分析和报告方面更加严格。
{"title":"Meditation practices for health: state of the research.","authors":"Maria B Ospina,&nbsp;Kenneth Bond,&nbsp;Mohammad Karkhaneh,&nbsp;Lisa Tjosvold,&nbsp;Ben Vandermeer,&nbsp;Yuanyuan Liang,&nbsp;Liza Bialy,&nbsp;Nicola Hooton,&nbsp;Nina Buscemi,&nbsp;Donna M Dryden,&nbsp;Terry P Klassen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>To review and synthesize the state of research on a variety of meditation practices, including: the specific meditation practices examined; the research designs employed and the conditions and outcomes examined; the efficacy and effectiveness of different meditation practices for the three most studied conditions; the role of effect modifiers on outcomes; and the effects of meditation on physiological and neuropsychological outcomes.</p><p><strong>Data sources: </strong>Comprehensive searches were conducted in 17 electronic databases of medical and psychological literature up to September 2005. Other sources of potentially relevant studies included hand searches, reference tracking, contact with experts, and gray literature searches.</p><p><strong>Review methods: </strong>A Delphi method was used to develop a set of parameters to describe meditation practices. Included studies were comparative, on any meditation practice, had more than 10 adult participants, provided quantitative data on health-related outcomes, and published in English. Two independent reviewers assessed study relevance, extracted the data and assessed the methodological quality of the studies.</p><p><strong>Results: </strong>Five broad categories of meditation practices were identified (Mantra meditation, Mindfulness meditation, Yoga, Tai Chi, and Qi Gong). Characterization of the universal or supplemental components of meditation practices was precluded by the theoretical and terminological heterogeneity among practices. Evidence on the state of research in meditation practices was provided in 813 predominantly poor-quality studies. The three most studied conditions were hypertension, other cardiovascular diseases, and substance abuse. Sixty-five intervention studies examined the therapeutic effect of meditation practices for these conditions. Meta-analyses based on low-quality studies and small numbers of hypertensive participants showed that TM(R), Qi Gong and Zen Buddhist meditation significantly reduced blood pressure. Yoga helped reduce stress. Yoga was no better than Mindfulness-based Stress Reduction at reducing anxiety in patients with cardiovascular diseases. No results from substance abuse studies could be combined. The role of effect modifiers in meditation practices has been neglected in the scientific literature. The physiological and neuropsychological effects of meditation practices have been evaluated in 312 poor-quality studies. Meta-analyses of results from 55 studies indicated that some meditation practices produced significant changes in healthy participants.</p><p><strong>Conclusions: </strong>Many uncertainties surround the practice of meditation. Scientific research on meditation practices does not appear to have a common theoretical perspective and is characterized by poor methodological quality. Firm conclusions on the effects of meditation practices in healthcare cannot be drawn based on the available evidence. Future r","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 155","pages":"1-263"},"PeriodicalIF":0.0,"publicationDate":"2007-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26948283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction. 心脏再同步化治疗和植入式心脏除颤器治疗左室收缩功能障碍。
Finlay A McAlister, Justin Ezekowitz, Donna M Dryden, Nicola Hooton, Ben Vandermeer, Carol Friesen, Carol Spooner, Brian H Rowe

Objectives: To determine the efficacy, effectiveness, and safety of cardiac resynchronization therapy (CRT) and/or implantable cardioverter defibrillators (ICD) in patients with left ventricular systolic dysfunction (LVSD).

Data sources: A systematic and comprehensive literature search was conducted to identify randomized controlled trials (RCTs) evaluating efficacy and observational studies evaluating effectiveness or safety of CRT and/or ICD in patients with LVSD.

Review methods: Study selection, quality assessment, and data extraction were completed by several investigators in duplicate and independently. Random-effects models were used for analyses.

Results: From 11,340 citations, we identified 14 RCTs (4,420 patients) for the CRT efficacy review, 106 studies (9,209 patients) for the CRT effectiveness review, 89 studies (9,677 patients) for the CRT safety review, 12 RCTs (8,516 patients) for the ICD efficacy review, 48 studies (15,097 patients) for the ICD effectiveness review, and 49 studies (12,592 patients) for the ICD safety review-all studies enrolled only patients with LVSD. An additional 12 studies (68,848 patients) were included for an analysis of peri-implant outcomes for all patients with ICD (i.e., not only LVSD patients). All patients in the CRT studies had LVSD (mean LVEF from 21 to 30 percent) and prolonged QRS duration (mean from 155 to 209 msec), and 91 percent had New York Heart Association (NYHA) class III or IV symptoms. In patients with LVSD and heart failure symptoms, CRT improved ejection fraction (weighted mean difference 3.0 percent [95% CI, 0.9 to 5.1]), quality of life (weighted mean reduction in Minnesota Living with Heart Failure Questionnaire 8.0 points [95% CI, 5.6 to 10.4 points]), and function (59 percent of CRT recipients vs. 37 percent of controls improved by at least one NYHA class in the RCTs and between 63 percent and 82 percent of CRT recipients improved by at least one NYHA class in observational studies). The proportion of patients hospitalized for HF was reduced by 37 percent (95% CI, 7 to 57 percent) and all-cause mortality was reduced by 22 percent (95% CI, 9 to 33 percent; NNT=29 over 6 months). Implant success rate was 93 percent, 0.3 percent of patients with LVSD died during implantation. Over a median 11-month followup, 6.6 percent of CRT devices exhibited lead problems and 5 percent malfunctioned. In patients with LVSD, ICD reduced all-cause mortality by 20 percent (95% CI, 10 to 29 percent; NNT=20 over 35 months). ICD implant success rate was 99 percent and peri-implant deaths occurred in 1.2 percent of LVSD patients and 1.3 percent of all implantees. The frequency of post-implantation complications in LVSD patients per 100 patient years included 1.4 (95% CI, 1.2 to 1.6) device malfunctions, 1.5 (95% CI, 1.3 to 1.8) lead problems, 0.6 (95% CI, 0.5 to 0.8) implant site infections, and 19.1 (95% CI, 16.5 to 2

目的:确定心脏再同步化治疗(CRT)和/或植入式心律转复除颤器(ICD)在左心室收缩功能障碍(LVSD)患者中的疗效、有效性和安全性。资料来源:我们进行了系统全面的文献检索,以确定评价CRT和/或ICD对LVSD患者疗效的随机对照试验(rct)和评价CRT和/或ICD有效性或安全性的观察性研究。综述方法:研究选择、质量评估和数据提取由多名研究者独立完成。随机效应模型用于分析。结果:从11340次引用中,我们确定了14项随机对照试验(4420例患者)用于CRT疗效评价,106项研究(9209例患者)用于CRT疗效评价,89项研究(9677例患者)用于CRT安全性评价,12项随机对照试验(8516例患者)用于ICD疗效评价,48项研究(15097例患者)用于ICD疗效评价,49项研究(12592例患者)用于ICD安全性评价,所有研究均仅纳入LVSD患者。另外纳入了12项研究(68,848例患者),分析了所有ICD患者(即不只是LVSD患者)的种植体周围结局。CRT研究中的所有患者都有LVSD(平均LVEF从21%到30%)和QRS持续时间延长(平均155到209毫秒),91%有纽约心脏协会(NYHA) III级或IV级症状。在LVSD和心力衰竭症状的患者中,CRT改善了射血分数(加权平均差3.0% [95% CI, 0.9至5.1]),生活质量(明尼苏达州心力衰竭生活问卷加权平均降低8.0分[95% CI, 5.6至10.4分]),(在随机对照试验中,59%的CRT接受者对37%的对照组至少有一个NYHA类别的改善,在观察性研究中,63%至82%的CRT接受者至少有一个NYHA类别的改善)。因心衰住院的患者比例降低了37% (95% CI, 7 - 57%),全因死亡率降低了22% (95% CI, 9 - 33%;NNT=29,超过6个月)。植入成功率为93%,0.3%的LVSD患者在植入过程中死亡。在平均11个月的随访中,6.6%的CRT设备出现铅问题,5%出现故障。在LVSD患者中,ICD使全因死亡率降低了20% (95% CI, 10%至29%;NNT=20,超过35个月)。ICD植入成功率为99%,植入期死亡发生率为1.2%的LVSD患者和1.3%的所有植入者。每100例患者年LVSD患者植入后并发症的频率包括1.4例(95% CI, 1.2 ~ 1.6)器械故障,1.5例(95% CI, 1.3 ~ 1.8)导联问题,0.6例(95% CI, 0.5 ~ 0.8)种植体部位感染,RCT参与者中19.1例(95% CI, 16.5 ~ 22.0)不适当出院,观察性研究中4.7例(95% CI, 4.3 ~ 5.1)不适当出院。结论:ICD和CRT降低了符合RCT入组标准的LVSD患者的全因死亡率。在LVSD患者中,CRT + ICD比单独CRT的增量效益仍不确定。没有一项试验报告CRT或ICD的疗效在患者亚组之间存在差异,我们的meta回归也没有发现任何亚组效应;然而,亚组分析和使用综合试验数据的元回归是事后分析,不足以检测到这种影响。迫切需要对个体患者试验数据进行检查,以确定哪些临床亚组最有可能从这些设备中受益。
{"title":"Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction.","authors":"Finlay A McAlister,&nbsp;Justin Ezekowitz,&nbsp;Donna M Dryden,&nbsp;Nicola Hooton,&nbsp;Ben Vandermeer,&nbsp;Carol Friesen,&nbsp;Carol Spooner,&nbsp;Brian H Rowe","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>To determine the efficacy, effectiveness, and safety of cardiac resynchronization therapy (CRT) and/or implantable cardioverter defibrillators (ICD) in patients with left ventricular systolic dysfunction (LVSD).</p><p><strong>Data sources: </strong>A systematic and comprehensive literature search was conducted to identify randomized controlled trials (RCTs) evaluating efficacy and observational studies evaluating effectiveness or safety of CRT and/or ICD in patients with LVSD.</p><p><strong>Review methods: </strong>Study selection, quality assessment, and data extraction were completed by several investigators in duplicate and independently. Random-effects models were used for analyses.</p><p><strong>Results: </strong>From 11,340 citations, we identified 14 RCTs (4,420 patients) for the CRT efficacy review, 106 studies (9,209 patients) for the CRT effectiveness review, 89 studies (9,677 patients) for the CRT safety review, 12 RCTs (8,516 patients) for the ICD efficacy review, 48 studies (15,097 patients) for the ICD effectiveness review, and 49 studies (12,592 patients) for the ICD safety review-all studies enrolled only patients with LVSD. An additional 12 studies (68,848 patients) were included for an analysis of peri-implant outcomes for all patients with ICD (i.e., not only LVSD patients). All patients in the CRT studies had LVSD (mean LVEF from 21 to 30 percent) and prolonged QRS duration (mean from 155 to 209 msec), and 91 percent had New York Heart Association (NYHA) class III or IV symptoms. In patients with LVSD and heart failure symptoms, CRT improved ejection fraction (weighted mean difference 3.0 percent [95% CI, 0.9 to 5.1]), quality of life (weighted mean reduction in Minnesota Living with Heart Failure Questionnaire 8.0 points [95% CI, 5.6 to 10.4 points]), and function (59 percent of CRT recipients vs. 37 percent of controls improved by at least one NYHA class in the RCTs and between 63 percent and 82 percent of CRT recipients improved by at least one NYHA class in observational studies). The proportion of patients hospitalized for HF was reduced by 37 percent (95% CI, 7 to 57 percent) and all-cause mortality was reduced by 22 percent (95% CI, 9 to 33 percent; NNT=29 over 6 months). Implant success rate was 93 percent, 0.3 percent of patients with LVSD died during implantation. Over a median 11-month followup, 6.6 percent of CRT devices exhibited lead problems and 5 percent malfunctioned. In patients with LVSD, ICD reduced all-cause mortality by 20 percent (95% CI, 10 to 29 percent; NNT=20 over 35 months). ICD implant success rate was 99 percent and peri-implant deaths occurred in 1.2 percent of LVSD patients and 1.3 percent of all implantees. The frequency of post-implantation complications in LVSD patients per 100 patient years included 1.4 (95% CI, 1.2 to 1.6) device malfunctions, 1.5 (95% CI, 1.3 to 1.8) lead problems, 0.6 (95% CI, 0.5 to 0.8) implant site infections, and 19.1 (95% CI, 16.5 to 2","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 152","pages":"1-199"},"PeriodicalIF":0.0,"publicationDate":"2007-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26946034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. 遗传性非息肉病性结直肠癌:诊断策略及其意义。
Peter A Bonis, Thomas A Trikalinos, Mei Chung, Priscilla Chew, Stanley Ip, Deirdre A DeVine, Joseph Lau

Objectives: Hereditary Nonpolyposis Colorectal Cancer (HNPCC) has been defined clinically and genetically. The disorder has traditionally been recognized in kindreds with a clustering of related cancers in association with mutations in DNA mismatch repair genes. HNPCC is associated with a substantially increased risk for several forms of malignancy but particularly colorectal and endometrial cancer. There were three main objectives of this report: (1) to assess the sensitivity, specificity, and reliability of laboratory and genetic tests commonly used in evaluating patients for HNPCC (analytic validity); (2) to summarize the accuracy of commonly used clinical and laboratory characteristics for predicting the presence of HNPCC in patients with colorectal cancer (clinical validity) and use these estimates to describe the efficiency of various strategies for identifying patients with a mismatch repair mutation; (3) to describe the benefits and harms related to screening and testing patients with colorectal cancer and their family members for HNPCC.

Data sources: Published literature identified through an electronic search (through April 2006), review of relevant bibliographies, and suggestions from technical experts.

Review methods: We evaluated studies critically and summarized the data qualitatively or by meta-analysis when studies used similar methodology and endpoints. We used decision trees to describe the efficiency of various strategies for identifying patients with HNPCC from a hypothetical population of patients with colorectal cancer.

Results: We included a total of 104 studies of which 40 addressed issues related to clinical validity, 3 to analytic validity, and 61 to benefits and harms. We identified only three studies on analytic validity and thus there exists a major gap in the published literature with regard to the accuracy and reliability of specific tests used in the evaluation of HNPCC. Among unselected patients with colorectal cancer who fulfilled the Amsterdam I criteria, 44% (95% CI: 35, 52%) carried pathogenic mismatch repair mutations (mainly in the MLH1 and MSH2 genes). The proportion was somewhat higher (51% [95% CI: 35, 66%]) among studies that performed sequencing on all available samples. The prevalence of MMR mutation carriers may be higher when genetic testing includes evaluation for large genomic deletions/rearrangements and when testing is also performed on MSH6 and PMS2. Approximately 71% (95% CI 63, 78%) of colorectal cancers from patients who fulfilled the Amsterdam I criteria demonstrated microsatellite instability while 40% (95% CI: 28, 53%) demonstrated loss of protein expression by immunohistochemistry. Of nine clinical strategies considered for detecting the presence of mismatch repair mutations in patients with colorectal cancer, the combination of three clinical predictors (age less than 50 years old at diagnosis; or a

目的:遗传性非息肉病性结直肠癌(HNPCC)的临床和遗传学定义。这种疾病传统上被认为是在与DNA错配修复基因突变相关的一系列相关癌症的亲属中。HNPCC与多种恶性肿瘤的风险显著增加有关,尤其是结直肠癌和子宫内膜癌。本报告有三个主要目的:(1)评估用于评估HNPCC患者的实验室和基因检测的敏感性、特异性和可靠性(分析效度);(2)总结预测结直肠癌患者中HNPCC存在的常用临床和实验室特征的准确性(临床效度),并使用这些估计来描述识别错配修复突变患者的各种策略的效率;(3)描述结直肠癌患者及其家属进行HNPCC筛查和检测的利与弊。数据来源:通过电子检索(截至2006年4月)确定的已发表文献、相关参考书目的审查以及技术专家的建议。回顾方法:我们对研究进行批判性评价,并对使用类似方法和终点的研究进行定性或荟萃分析总结数据。我们使用决策树来描述从假设的结直肠癌患者人群中识别HNPCC患者的各种策略的效率。结果:我们共纳入104项研究,其中40项涉及临床效度,3项涉及分析效度,61项涉及益处和危害。我们只确定了三个分析效度的研究,因此,在已发表的文献中,关于用于评估HNPCC的特定测试的准确性和可靠性存在重大差距。在未入选的符合阿姆斯特丹I型标准的结直肠癌患者中,44% (95% CI: 35,52%)携带致病性错配修复突变(主要在MLH1和MSH2基因中)。在对所有可用样本进行测序的研究中,这一比例略高(51% [95% CI: 35,66%])。当基因检测包括对大基因组缺失/重排的评估以及同时对MSH6和PMS2进行检测时,MMR突变携带者的患病率可能更高。约71% (95% CI: 63.78%)符合Amsterdam I标准的结直肠癌患者表现出微卫星不稳定性,而40% (95% CI: 28.53%)通过免疫组化表现出蛋白质表达缺失。在检测结直肠癌患者错配修复突变存在的九种临床策略中,三个临床预测因素的组合(诊断时年龄小于50岁;或有一级家族成员有结直肠癌或子宫内膜癌病史;或先证中存在多个、同步或异时性结直肠癌或子宫内膜癌),结合肿瘤组织的免疫组化(IHC)或MSI检测,发现了与其他更复杂的策略相似数量的错配修复突变患者。关于使用临床标准(如阿姆斯特丹标准)、MSI或IHC检测筛查hnpcc相关癌症患者的潜在危害的已发表信息很少。有限的数据表明,在正式咨询后,检测MMR突变的先证者与严重的心理影响无关。检测前遗传咨询对提高对HNPCC的认识、提高进行基因检测的可能性、提高决定进行基因检测的满意度、降低患癌的HNPCC先证家庭成员和无症状的HNPCC家庭成员的抑郁和痛苦水平具有良好的效果。HNPCC突变的鉴定与患结直肠癌的先证者的家庭成员接受癌症筛查程序的可能性增加有关。接受癌症筛查的HNPCC家庭成员患HNPCC相关癌症的风险较低,死亡率低于未接受筛查的家庭成员。然而,所有表明这些益处的相关研究都有重要的局限性。接受结肠镜筛查的无症状HNPCC家族成员的生存率增加,无论其突变状态如何。在HNPCC先证者的家庭成员中,与癌症筛查程序的危害相关的直接证据有限。然而,在其他情况下,与这些手术相关的并发症发生率可能相似。结论:本报告描述了MMR突变的临床和实验室预测的准确性,可用于识别MMR突变风险增加的患者。 然而,用于评估疑似HNPCC个体的检测的敏感性、特异性和可靠性尚不清楚。关于在hnpcc相关癌症患者及其家庭成员中进行预测性基因检测的净收益和危害的数据不完整,但表明这种检测提高了筛查程序的依从性。接受结肠镜筛查的高危家庭成员患hnpcc相关癌症的风险降低,死亡率降低。然而,所有支持这些益处的研究都有重要的局限性。
{"title":"Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.","authors":"Peter A Bonis,&nbsp;Thomas A Trikalinos,&nbsp;Mei Chung,&nbsp;Priscilla Chew,&nbsp;Stanley Ip,&nbsp;Deirdre A DeVine,&nbsp;Joseph Lau","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Hereditary Nonpolyposis Colorectal Cancer (HNPCC) has been defined clinically and genetically. The disorder has traditionally been recognized in kindreds with a clustering of related cancers in association with mutations in DNA mismatch repair genes. HNPCC is associated with a substantially increased risk for several forms of malignancy but particularly colorectal and endometrial cancer. There were three main objectives of this report: (1) to assess the sensitivity, specificity, and reliability of laboratory and genetic tests commonly used in evaluating patients for HNPCC (analytic validity); (2) to summarize the accuracy of commonly used clinical and laboratory characteristics for predicting the presence of HNPCC in patients with colorectal cancer (clinical validity) and use these estimates to describe the efficiency of various strategies for identifying patients with a mismatch repair mutation; (3) to describe the benefits and harms related to screening and testing patients with colorectal cancer and their family members for HNPCC.</p><p><strong>Data sources: </strong>Published literature identified through an electronic search (through April 2006), review of relevant bibliographies, and suggestions from technical experts.</p><p><strong>Review methods: </strong>We evaluated studies critically and summarized the data qualitatively or by meta-analysis when studies used similar methodology and endpoints. We used decision trees to describe the efficiency of various strategies for identifying patients with HNPCC from a hypothetical population of patients with colorectal cancer.</p><p><strong>Results: </strong>We included a total of 104 studies of which 40 addressed issues related to clinical validity, 3 to analytic validity, and 61 to benefits and harms. We identified only three studies on analytic validity and thus there exists a major gap in the published literature with regard to the accuracy and reliability of specific tests used in the evaluation of HNPCC. Among unselected patients with colorectal cancer who fulfilled the Amsterdam I criteria, 44% (95% CI: 35, 52%) carried pathogenic mismatch repair mutations (mainly in the MLH1 and MSH2 genes). The proportion was somewhat higher (51% [95% CI: 35, 66%]) among studies that performed sequencing on all available samples. The prevalence of MMR mutation carriers may be higher when genetic testing includes evaluation for large genomic deletions/rearrangements and when testing is also performed on MSH6 and PMS2. Approximately 71% (95% CI 63, 78%) of colorectal cancers from patients who fulfilled the Amsterdam I criteria demonstrated microsatellite instability while 40% (95% CI: 28, 53%) demonstrated loss of protein expression by immunohistochemistry. Of nine clinical strategies considered for detecting the presence of mismatch repair mutations in patients with colorectal cancer, the combination of three clinical predictors (age less than 50 years old at diagnosis; or a ","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 150","pages":"1-180"},"PeriodicalIF":0.0,"publicationDate":"2007-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26946036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breastfeeding and maternal and infant health outcomes in developed countries. 发达国家的母乳喂养和母婴健康结果。
Stanley Ip, Mei Chung, Gowri Raman, Priscilla Chew, Nombulelo Magula, Deirdre DeVine, Thomas Trikalinos, Joseph Lau

Objectives: We reviewed the evidence on the effects of breastfeeding on short- and long-term infant and maternal health outcomes in developed countries.

Data sources: We searched MEDLINE(R), CINAHL, and the Cochrane Library in November of 2005. Supplemental searches on selected outcomes were searched through May of 2006. We also identified additional studies in bibliographies of selected reviews and by suggestions from technical experts.

Review methods: We included systematic reviews/meta-analyses, randomized and non-randomized comparative trials, prospective cohort, and case-control studies on the effects of breastfeeding and relevant outcomes published in the English language. Included studies must have a comparative arm of formula feeding or different durations of breastfeeding. Only studies conducted in developed countries were included in the updates of previous systematic reviews. The studies were graded for methodological quality.

Results: We screened over 9,000 abstracts. Forty-three primary studies on infant health outcomes, 43 primary studies on maternal health outcomes, and 29 systematic reviews or meta-analyses that covered approximately 400 individual studies were included in this review. We found that a history of breastfeeding was associated with a reduction in the risk of acute otitis media, non-specific gastroenteritis, severe lower respiratory tract infections, atopic dermatitis, asthma (young children), obesity, type 1 and 2 diabetes, childhood leukemia, sudden infant death syndrome (SIDS), and necrotizing enterocolitis. There was no relationship between breastfeeding in term infants and cognitive performance. The relationship between breastfeeding and cardiovascular diseases was unclear. Similarly, it was also unclear concerning the relationship between breastfeeding and infant mortality in developed countries. For maternal outcomes, a history of lactation was associated with a reduced risk of type 2 diabetes, breast, and ovarian cancer. Early cessation of breastfeeding or not breastfeeding was associated with an increased risk of maternal postpartum depression. There was no relationship between a history of lactation and the risk of osteoporosis. The effect of breastfeeding in mothers on return-to-pre-pregnancy weight was negligible, and the effect of breastfeeding on postpartum weight loss was unclear.

Conclusions: A history of breastfeeding is associated with a reduced risk of many diseases in infants and mothers from developed countries. Because almost all the data in this review were gathered from observational studies, one should not infer causality based on these findings. Also, there is a wide range of quality of the body of evidence across different health outcomes. For future studies, clear subject selection criteria and definition of "exclusive breastfeeding," reliable collection of feeding data, controlli

目的:我们回顾了发达国家母乳喂养对母婴短期和长期健康结果影响的证据。资料来源:我们于2005年11月检索MEDLINE(R)、CINAHL和Cochrane图书馆。对选定结果的补充搜索一直搜索到2006年5月。我们还根据技术专家的建议,在选定评论的参考书目中确定了其他研究。回顾方法:我们纳入了系统回顾/荟萃分析、随机和非随机比较试验、前瞻性队列研究和病例对照研究,这些研究涉及母乳喂养的影响以及以英语发表的相关结果。纳入的研究必须对配方奶喂养或不同母乳喂养时间进行比较。只有在发达国家进行的研究被纳入以前系统评价的更新。这些研究根据方法学质量进行了分级。结果:我们筛选了9000多篇摘要。本综述包括43项关于婴儿健康结果的主要研究,43项关于孕产妇健康结果的主要研究,以及29项系统评价或荟萃分析,涵盖了大约400项单独的研究。我们发现,母乳喂养史与急性中耳炎、非特异性胃肠炎、严重下呼吸道感染、特应性皮炎、哮喘(幼儿)、肥胖、1型和2型糖尿病、儿童白血病、婴儿猝死综合征(SIDS)和坏死性小肠结肠炎的风险降低有关。足月婴儿母乳喂养与认知能力之间没有关系。母乳喂养与心血管疾病之间的关系尚不清楚。同样,发达国家母乳喂养与婴儿死亡率之间的关系也不清楚。对于产妇的结局,泌乳史与2型糖尿病、乳腺癌和卵巢癌的风险降低有关。早期停止母乳喂养或不母乳喂养与母亲产后抑郁症的风险增加有关。泌乳史与骨质疏松风险之间没有关系。母亲母乳喂养对恢复孕前体重的影响可以忽略不计,母乳喂养对产后体重减轻的影响尚不清楚。结论:在发达国家,母乳喂养史与婴儿和母亲患多种疾病的风险降低有关。由于本综述中的几乎所有数据都来自观察性研究,因此不应根据这些发现推断因果关系。此外,不同健康结果的证据质量参差不齐。对于未来的研究,明确的受试者选择标准和“纯母乳喂养”的定义,可靠的喂养数据收集,控制包括儿童特定因素在内的重要混杂因素,以及对结果测量的盲法评估将有所帮助。兄弟姐妹分析提供了一种控制遗传和家庭因素的方法,这些因素对某些结果很重要。此外,关于各种促进母乳喂养干预措施有效性的整群随机对照研究将为调查干预措施在健康结果方面的任何差异提供进一步的机会。
{"title":"Breastfeeding and maternal and infant health outcomes in developed countries.","authors":"Stanley Ip,&nbsp;Mei Chung,&nbsp;Gowri Raman,&nbsp;Priscilla Chew,&nbsp;Nombulelo Magula,&nbsp;Deirdre DeVine,&nbsp;Thomas Trikalinos,&nbsp;Joseph Lau","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>We reviewed the evidence on the effects of breastfeeding on short- and long-term infant and maternal health outcomes in developed countries.</p><p><strong>Data sources: </strong>We searched MEDLINE(R), CINAHL, and the Cochrane Library in November of 2005. Supplemental searches on selected outcomes were searched through May of 2006. We also identified additional studies in bibliographies of selected reviews and by suggestions from technical experts.</p><p><strong>Review methods: </strong>We included systematic reviews/meta-analyses, randomized and non-randomized comparative trials, prospective cohort, and case-control studies on the effects of breastfeeding and relevant outcomes published in the English language. Included studies must have a comparative arm of formula feeding or different durations of breastfeeding. Only studies conducted in developed countries were included in the updates of previous systematic reviews. The studies were graded for methodological quality.</p><p><strong>Results: </strong>We screened over 9,000 abstracts. Forty-three primary studies on infant health outcomes, 43 primary studies on maternal health outcomes, and 29 systematic reviews or meta-analyses that covered approximately 400 individual studies were included in this review. We found that a history of breastfeeding was associated with a reduction in the risk of acute otitis media, non-specific gastroenteritis, severe lower respiratory tract infections, atopic dermatitis, asthma (young children), obesity, type 1 and 2 diabetes, childhood leukemia, sudden infant death syndrome (SIDS), and necrotizing enterocolitis. There was no relationship between breastfeeding in term infants and cognitive performance. The relationship between breastfeeding and cardiovascular diseases was unclear. Similarly, it was also unclear concerning the relationship between breastfeeding and infant mortality in developed countries. For maternal outcomes, a history of lactation was associated with a reduced risk of type 2 diabetes, breast, and ovarian cancer. Early cessation of breastfeeding or not breastfeeding was associated with an increased risk of maternal postpartum depression. There was no relationship between a history of lactation and the risk of osteoporosis. The effect of breastfeeding in mothers on return-to-pre-pregnancy weight was negligible, and the effect of breastfeeding on postpartum weight loss was unclear.</p><p><strong>Conclusions: </strong>A history of breastfeeding is associated with a reduced risk of many diseases in infants and mothers from developed countries. Because almost all the data in this review were gathered from observational studies, one should not infer causality based on these findings. Also, there is a wide range of quality of the body of evidence across different health outcomes. For future studies, clear subject selection criteria and definition of \"exclusive breastfeeding,\" reliable collection of feeding data, controlli","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 153","pages":"1-186"},"PeriodicalIF":0.0,"publicationDate":"2007-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26950334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nurse staffing and quality of patient care. 护士人员配备和病人护理质量。
Robert L Kane, Tatyana Shamliyan, Christine Mueller, Sue Duval, T J Wilt

Objectives: To assess how nurse to patient ratios and nurse work hours were associated with patient outcomes in acute care hospitals, factors that influence nurse staffing policies, and nurse staffing strategies that improved patient outcomes.

Data sources: MEDLINE (PubMed), CINAHL, Cochrane Databases, EBSCO research database, BioMed Central, Federal reports, National Database of Nursing Quality Indicators, National Center for Workforce Analysis, American Nurses Association, American Academy of Nurse Practitioners, and Digital Dissertations.

Review methods: In the absence of randomized controlled trials, observational studies were reviewed to examine the relationship between nurse staffing and outcomes. Meta-analysis tested the consistency of the association between nurse staffing and patient outcomes; classes of patient and hospital characteristics were analyzed separately.

Results: Higher registered nurse staffing was associated with less hospital-related mortality, failure to rescue, cardiac arrest, hospital acquired pneumonia, and other adverse events. The effect of increased registered nurse staffing on patients safety was strong and consistent in intensive care units and in surgical patients. Greater registered nurse hours spent on direct patient care were associated with decreased risk of hospital-related death and shorter lengths of stay. Limited evidence suggests that the higher proportion of registered nurses with BSN degrees was associated with lower mortality and failure to rescue. More overtime hours were associated with an increase in hospital related mortality, nosocomial infections, shock, and bloodstream infections. No studies directly examined the factors that influence nurse staffing policy. Few studies addressed the role of agency staff. No studies evaluated the role of internationally educated nurse staffing policies.

Conclusions: Increased nursing staffing in hospitals was associated with lower hospital-related mortality, failure to rescue, and other patient outcomes, but the association is not necessarily causal. The effect size varied with the nurse staffing measure, the reduction in relative risk was greater and more consistent across the studies, corresponding to an increased registered nurse to patient ratio but not hours and skill mix. Estimates of the size of the nursing effect must be tempered by provider characteristics including hospital commitment to high quality care not considered in most of the studies. Greater nurse staffing was associated with better outcomes in intensive care units and in surgical patients.

目的:评估急症护理医院护患比例和护士工作时数与患者预后的关系、影响护士人员配置政策的因素以及改善患者预后的护士人员配置策略。数据来源:MEDLINE (PubMed)、CINAHL、Cochrane数据库、EBSCO研究数据库、BioMed Central、联邦报告、国家护理质量指标数据库、国家劳动力分析中心、美国护士协会、美国护士从业人员学会和数字论文。回顾方法:在缺乏随机对照试验的情况下,回顾观察性研究,以检查护士配备与结果之间的关系。meta分析检验了护士配备与患者预后之间相关性的一致性;分别分析患者类别和医院特征。结果:较高的注册护士配备与较低的医院相关死亡率、抢救失败、心脏骤停、医院获得性肺炎和其他不良事件相关。在重症监护病房和外科患者中,增加注册护士人员对患者安全的影响是强烈和一致的。注册护士直接护理病人的时间越长,医院相关死亡风险越低,住院时间越短。有限的证据表明,拥有BSN学位的注册护士比例较高与较低的死亡率和抢救失败相关。加班时间越长,与医院相关死亡率、医院感染、休克和血液感染的增加有关。没有研究直接调查影响护士人员配置政策的因素。很少有研究涉及机构工作人员的作用。没有研究评估国际教育护士人员配置政策的作用。结论:医院护理人员的增加与较低的医院相关死亡率、抢救失败和其他患者结局相关,但这种关联不一定是因果关系。效应大小随护士配备措施的不同而变化,相对风险的降低更大,在研究中更一致,对应于注册护士与患者比例的增加,但与工作时间和技能组合无关。对护理效果大小的估计必须根据提供者的特征进行调整,包括大多数研究中未考虑的医院对高质量护理的承诺。在重症监护病房和外科病人中,更多的护士配备与更好的结果相关。
{"title":"Nurse staffing and quality of patient care.","authors":"Robert L Kane,&nbsp;Tatyana Shamliyan,&nbsp;Christine Mueller,&nbsp;Sue Duval,&nbsp;T J Wilt","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>To assess how nurse to patient ratios and nurse work hours were associated with patient outcomes in acute care hospitals, factors that influence nurse staffing policies, and nurse staffing strategies that improved patient outcomes.</p><p><strong>Data sources: </strong>MEDLINE (PubMed), CINAHL, Cochrane Databases, EBSCO research database, BioMed Central, Federal reports, National Database of Nursing Quality Indicators, National Center for Workforce Analysis, American Nurses Association, American Academy of Nurse Practitioners, and Digital Dissertations.</p><p><strong>Review methods: </strong>In the absence of randomized controlled trials, observational studies were reviewed to examine the relationship between nurse staffing and outcomes. Meta-analysis tested the consistency of the association between nurse staffing and patient outcomes; classes of patient and hospital characteristics were analyzed separately.</p><p><strong>Results: </strong>Higher registered nurse staffing was associated with less hospital-related mortality, failure to rescue, cardiac arrest, hospital acquired pneumonia, and other adverse events. The effect of increased registered nurse staffing on patients safety was strong and consistent in intensive care units and in surgical patients. Greater registered nurse hours spent on direct patient care were associated with decreased risk of hospital-related death and shorter lengths of stay. Limited evidence suggests that the higher proportion of registered nurses with BSN degrees was associated with lower mortality and failure to rescue. More overtime hours were associated with an increase in hospital related mortality, nosocomial infections, shock, and bloodstream infections. No studies directly examined the factors that influence nurse staffing policy. Few studies addressed the role of agency staff. No studies evaluated the role of internationally educated nurse staffing policies.</p><p><strong>Conclusions: </strong>Increased nursing staffing in hospitals was associated with lower hospital-related mortality, failure to rescue, and other patient outcomes, but the association is not necessarily causal. The effect size varied with the nurse staffing measure, the reduction in relative risk was greater and more consistent across the studies, corresponding to an increased registered nurse to patient ratio but not hours and skill mix. Estimates of the size of the nursing effect must be tempered by provider characteristics including hospital commitment to high quality care not considered in most of the studies. Greater nurse staffing was associated with better outcomes in intensive care units and in surgical patients.</p>","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 151","pages":"1-115"},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26950326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 选择性血清素再摄取抑制剂(SSRIs)治疗的非精神病性抑郁症成人细胞色素P450多态性检测
David B Matchar, Mugdha E Thakur, Iris Grossman, Douglas C McCrory, Lori A Orlando, David C Steffens, David B Goldstein, Kathryn E Cline, Rebecca N Gray

Objectives: To determine if testing for cytochrome P450 (CYP450) polymorphisms in adults entering selective serotonin reuptake inhibitor (SSRI) treatment for non-psychotic depression leads to improvement in outcomes, or if testing results are useful in medical, personal, or public health decisionmaking.

Data sources: We searched MEDLINE, the Cochrane Database of Abstracts of Reviews of Effects, PsychInfo, HealthSTAR, and CINAHL, and reviewed the reference lists of included articles and relevant review articles and meta-analyses for eligible studies. We also included documents from the U.S. Food and Drug Administration (FDA) that could be publicly accessed.

Review methods: We developed an analytic framework and identified key questions to guide the review process. Project-specific inclusion/exclusion criteria were also developed and were used by paired researchers independently to review both abstracts and full-text articles; both researchers were required to agree on inclusion status at the full-text stage. Abstractors evaluated each included article for factors affecting internal and external validity.

Results: A review of 1,200 abstracts led to the final inclusion of 37 articles. The evidence indicates the existence of tests with high sensitivity and specificity for detecting only a few of the more common known polymorphisms of 2D6, 2C19, 2C8, 2C9, and 1A1. There is mixed evidence regarding the association between CYP450 genotypes and SSRI metabolism, efficacy, and tolerability in the treatment of depression, mainly from a series of heterogeneous studies in small samples. There are no data regarding: (a) if testing for CYP450 polymorphisms in adults entering SSRI treatment for non-psychotic depression leads to improvement in outcomes versus not testing, or if testing results are useful in medical, personal, or public health decisionmaking; (b) if CYP450 testing influences depression management decisions by patients and providers in ways that could improve or worsen outcomes; or (c) if there are direct or indirect harms associated with testing for CYP450 polymorphisms or with subsequent management options.

Conclusions: There is a paucity of good-quality data addressing the questions of whether testing for CYP450 polymorphisms in adults entering SSRI treatment for non-psychotic depression leads to improvement in outcomes, or whether testing results are useful in medical, personal, or public health decisionmaking.

目的:确定在接受选择性血清素再摄取抑制剂(SSRI)治疗的非精神病性抑郁症成人中,检测细胞色素P450 (CYP450)多态性是否会改善预后,或者检测结果是否对医疗、个人或公共卫生决策有用。数据来源:我们检索了MEDLINE、Cochrane Effects综述摘要数据库、PsychInfo、HealthSTAR和CINAHL,并查阅了纳入文章的参考文献列表、相关综述文章和符合条件的研究的荟萃分析。我们还包括了可以公开访问的美国食品和药物管理局(FDA)的文件。评审方法:我们开发了一个分析框架,并确定了关键问题来指导评审过程。还制定了特定于项目的纳入/排除标准,并由成对的研究人员独立地用于审查摘要和全文文章;在全文阶段,两位研究人员都必须同意纳入状态。摘要对每篇纳入的文章进行评估,以确定影响内部效度和外部效度的因素。结果:对1200篇摘要进行综述,最终纳入37篇。有证据表明,对于检测2D6、2C19、2C8、2C9和1A1的少数常见多态性,存在高灵敏度和特异性的测试。关于CYP450基因型与SSRI代谢、疗效和治疗抑郁症耐受性之间的关系,主要来自一系列小样本的异质性研究,证据不一。没有关于以下方面的数据:(a)与不检测相比,在接受SSRI治疗的非精神病性抑郁症的成人中检测CYP450多态性是否会导致结果的改善,或者检测结果是否对医疗、个人或公共卫生决策有用;(b) CYP450检测是否会以可能改善或恶化结果的方式影响患者和提供者的抑郁症管理决策;或(c)是否与CYP450多态性检测或后续管理方案相关的直接或间接危害。结论:对于接受非精神病性抑郁症SSRI治疗的成人,检测CYP450多态性是否会改善预后,或者检测结果是否对医疗、个人或公共卫生决策有用,目前缺乏高质量的数据。
{"title":"Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).","authors":"David B Matchar,&nbsp;Mugdha E Thakur,&nbsp;Iris Grossman,&nbsp;Douglas C McCrory,&nbsp;Lori A Orlando,&nbsp;David C Steffens,&nbsp;David B Goldstein,&nbsp;Kathryn E Cline,&nbsp;Rebecca N Gray","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>To determine if testing for cytochrome P450 (CYP450) polymorphisms in adults entering selective serotonin reuptake inhibitor (SSRI) treatment for non-psychotic depression leads to improvement in outcomes, or if testing results are useful in medical, personal, or public health decisionmaking.</p><p><strong>Data sources: </strong>We searched MEDLINE, the Cochrane Database of Abstracts of Reviews of Effects, PsychInfo, HealthSTAR, and CINAHL, and reviewed the reference lists of included articles and relevant review articles and meta-analyses for eligible studies. We also included documents from the U.S. Food and Drug Administration (FDA) that could be publicly accessed.</p><p><strong>Review methods: </strong>We developed an analytic framework and identified key questions to guide the review process. Project-specific inclusion/exclusion criteria were also developed and were used by paired researchers independently to review both abstracts and full-text articles; both researchers were required to agree on inclusion status at the full-text stage. Abstractors evaluated each included article for factors affecting internal and external validity.</p><p><strong>Results: </strong>A review of 1,200 abstracts led to the final inclusion of 37 articles. The evidence indicates the existence of tests with high sensitivity and specificity for detecting only a few of the more common known polymorphisms of 2D6, 2C19, 2C8, 2C9, and 1A1. There is mixed evidence regarding the association between CYP450 genotypes and SSRI metabolism, efficacy, and tolerability in the treatment of depression, mainly from a series of heterogeneous studies in small samples. There are no data regarding: (a) if testing for CYP450 polymorphisms in adults entering SSRI treatment for non-psychotic depression leads to improvement in outcomes versus not testing, or if testing results are useful in medical, personal, or public health decisionmaking; (b) if CYP450 testing influences depression management decisions by patients and providers in ways that could improve or worsen outcomes; or (c) if there are direct or indirect harms associated with testing for CYP450 polymorphisms or with subsequent management options.</p><p><strong>Conclusions: </strong>There is a paucity of good-quality data addressing the questions of whether testing for CYP450 polymorphisms in adults entering SSRI treatment for non-psychotic depression leads to improvement in outcomes, or whether testing results are useful in medical, personal, or public health decisionmaking.</p>","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 146","pages":"1-77"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26950329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Evidence report/technology assessment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1